SpringWorks Therapeutics Inc. (NASDAQ:SWTX) price closed lower on Friday, September 15, dropping -1.97% below its previous close.
A look at the daily price movement shows that the last close reads $26.87, with intraday deals fluctuated between $25.98 and $27.8062. Taking into account the 52-week price action we note that the stock hit a 52-week high of $34.16 and 52-week low of $21.04. The stock subtracted -7.48% on its value in the past month.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
SpringWorks Therapeutics Inc., which has a market valuation of $1.68 billion. Analysts tracking SWTX have forecast the quarterly EPS to shrink by -1.33 per share this quarter, while the same analysts predict the annual EPS to hit -$5.21 for the year 2023 and up to -$4.13 for 2024.
Staying with the analyst view, there is a consensus estimate of $2.77 million for the company’s annual revenue in 2023.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give SWTX a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Buy, while an average of long term indicators are currently assigning the stock as 50% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 7 analysts have assigned SWTX a recommendation rating as follows: 0 rate it as a Hold; 6 advise Buy while 1 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the SpringWorks Therapeutics Inc. (SWTX) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that SWTX’s price is at present -5.30% off the SMA20 and -6.04% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 42.00, with weekly volatility standing at 4.04%. The indicator jumps to 5.77% when calculated based on the past 30 days. SpringWorks Therapeutics Inc. (NASDAQ:SWTX)’s beta value is holding at 0.58, while the average true range (ATR) indicator is currently reading 1.44. Considering analysts have assigned the stock a price target range of $41.00-$66.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $50.17. Based on this estimate, we see that current price is roughly -55.66% off the estimated low and -150.57% off the forecast high. Investors will no doubt be excited to see the share price fall to $47.00, which is the median consensus price, and at that level SWTX would be -78.44% from current price.
Turning out attention to how the SpringWorks Therapeutics Inc. stock has performed in comparison to its peers in the industry, here’s what we find: SWTX’s stock is -1.97% on the day and -12.20% in the past 12 months. Another comparison is with Rogers Corporation (ROG) whose stock price was up 1.52% in the last trading session, and has flourished -44.60% over the past year. Also, AstraZeneca PLC (AZN) showed up trend of 0.72% while its price kept floating at 16.26% over the past year. Elsewhere in the market, the S&P 500 Index has stumbled -1.22% in last trading session, with the Dow Jones Industrial also saw a negative session on the day with -0.83%.
An analysis of the SpringWorks Therapeutics Inc. (NASDAQ:SWTX) stock in terms of its daily trading volume indicates that the 3-month average is 568.40K. However, this figure increases on the past 10-day timeline to an average of 0.65 million.
Current records show that the company has 62.46M in outstanding shares. The insiders’ percentage holdings are 0.50% of outstanding shares while the percentage share held by institutions stands at 110.34%. The stats also highlight that short interest as of Aug 30, 2023, stood at 14.53 million shares, which puts the short ratio at the time at 27.26. From this we can glean that short interest is 23.22% of company’s current outstanding shares. Notably, we see that shares short in August fall slightly given the previous month’s figure stood at 15.08 million. But the 1.27% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
